secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001104659-25-046955
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee reports Q1 net loss $55.3M; positive APG808 Phase 1b data with 53% FeNO suppression
--------------------------------------------------------------------------------

- Q1 net loss $55.3M vs $32.1M YoY; cash $681.4M supports runway into Q1 2028.
- Positive interim Phase 1b APG808 results: FeNO suppression 53% max, sustained 50% at 12 weeks; well tolerated.
- Phase 2 APEX trial of APG777 advancing; interim Part A 16-week data expected mid-2025.
- First patient dosed in Phase 1b APG777 asthma trial; readout expected 1H 2026.
- APG279 (APG777+APG990) head-to-head vs DUPIXENT on track to initiate in 2025; readout 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925046955/0001104659-25-046955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925046955/tm2514695d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-046955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer